The Medicines Co. (MDCO)

32.99
NASDAQ : Health Technology
Prev Close 33.10
Day Low/High 32.78 / 33.97
52 Wk Low/High 16.69 / 41.57
Avg Volume 984.90K
Exchange NASDAQ
Shares Outstanding 73.89M
Market Cap 2.45B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
New Long-Term Data Show That Twice-a-Year Dosing With Inclisiran Results In Persistent Lowering Of LDL Cholesterol With No Material Safety Observations Out To Three Years

New Long-Term Data Show That Twice-a-Year Dosing With Inclisiran Results In Persistent Lowering Of LDL Cholesterol With No Material Safety Observations Out To Three Years

The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density...

June 2020 Options Now Available For Medicines (MDCO)

June 2020 Options Now Available For Medicines (MDCO)

Investors in Medicines Co saw new options become available today, for the June 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 401 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Medicines Company To Host Investor Conference Call And Webcast During National Lipid Association's 2019 Scientific Sessions

The Medicines Company To Host Investor Conference Call And Webcast During National Lipid Association's 2019 Scientific Sessions

The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.

The Medicines Company To Participate In The Bank Of America Merrill Lynch 2019 Healthcare Conference

The Medicines Company To Participate In The Bank Of America Merrill Lynch 2019 Healthcare Conference

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas.

The Medicines Company Reports First-Quarter 2019 Financial Results And Significant Progress With The Inclisiran Clinical Development Program

The Medicines Company Reports First-Quarter 2019 Financial Results And Significant Progress With The Inclisiran Clinical Development Program

The Medicines Company (NASDAQ:MDCO) today reported financial results for the first quarter that ended March 31, 2019.

The Medicines Company To Announce First Quarter 2019 Financial Results On April 25

The Medicines Company To Announce First Quarter 2019 Financial Results On April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, April 25, 2019 at 8:30 a.

Insider Buying Is Still Alive and Well at These 3 Companies

Insider Buying Is Still Alive and Well at These 3 Companies

Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.

The Medicines Company Reports Fourth-Quarter And Full Year 2018 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full Year 2018 Business And Financial Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2018.

The Medicines Company Announces Upcoming Investor Conference Presentations

The Medicines Company Announces Upcoming Investor Conference Presentations

The Medicines Company (NASDAQ:MDCO) announced today that management will present company overviews at the following conferences: 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 9 a.

The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company (NASDAQ: MDCO) today announced that the 5 th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed.

MDCO: Insiders Vs. Shorts

MDCO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 11/30/2018 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 15.65 "days to cover" versus the median component at 5.06. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

The Medicines Company Prices $150 Million Of Convertible Notes

The Medicines Company Prices $150 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024.

The Medicines Company Announces Intention To Offer $150 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $150 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors.

The Medicines Company Appoints Mark Timney As Chief Executive Officer

The Medicines Company Appoints Mark Timney As Chief Executive Officer

The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company's new Chief Executive Officer and a member of the Board of Directors, effective immediately.

Company Profile For The Medicines Company

Company Profile For The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare.

The Medicines Company Reports Third-Quarter 2018 Results

The Medicines Company Reports Third-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the third quarter ended September 30, 2018.

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company (NASDAQ:MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company (NASDAQ: MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes...

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86 th European Atherosclerosis Society Congress (EAS 2018) and accepted for...

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV.

First Week Of June 15th Options Trading For Medicines (MDCO)

Investors in Medicines Co saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018.

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately.

TheStreet Quant Rating: D (Sell)